The identification of the optimal method or methodologies for the assessment of proliferative activity in breast cancer has been the subject of several previous studies in the last decade since the introduction of Ki-67 as a routinely assessed parameter in hormone receptor-positive breast cancer specimens1–12. The gene discussed is NR4A1; the disease is breast cancer.